Mustang Bio, Inc. 2W6.F Stock
Mustang Bio, Inc. Price Chart
Mustang Bio, Inc. 2W6.F Financial and Trading Overview
Mustang Bio, Inc. stock price | 0.32 EUR |
Previous Close | 0.32 EUR |
Open | 0.32 EUR |
Bid | 0 EUR x N/A |
Ask | 0 EUR x N/A |
Day's Range | 0.32 - 0.32 EUR |
52 Week Range | 0.32 - 11.89 EUR |
Volume | 500 EUR |
Avg. Volume | 0 EUR |
Market Cap | 35.27M EUR |
Beta (5Y Monthly) | N/A |
PE Ratio (TTM) | N/A |
EPS (TTM) | 0 EUR |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 10.4 EUR |
2W6.F Valuation Measures
Enterprise Value | N/A |
Trailing P/E | N/A |
Forward P/E | -0.4417808 |
PEG Ratio (5 yr expected) | N/A |
Price/Sales (ttm) | N/A |
Price/Book (mrq) | 0.53482586 |
Enterprise Value/Revenue | N/A |
Enterprise Value/EBITDA | N/A |
Trading Information
Mustang Bio, Inc. Stock Price History
Beta (5Y Monthly) | N/A |
52-Week Change | -56.22% |
S&P500 52-Week Change | 2.92% |
52 Week High | 11.89 EUR |
52 Week Low | 0.32 EUR |
50-Day Moving Average | 6.61 EUR |
200-Day Moving Average | 7.52 EUR |
2W6.F Share Statistics
Avg. Volume (3 month) | 0 EUR |
Avg. Daily Volume (10-Days) | 0 EUR |
Shares Outstanding | 109.37M |
Float | N/A |
Short Ratio | N/A |
% Held by Insiders | 21.37% |
% Held by Institutions | 11.23% |
Shares Short | N/A |
Short % of Float | N/A |
Short % of Shares Outstanding | N/A |
Dividends & Splits
Trailing Annual Dividend Rate | 0 |
Trailing Annual Dividend Yield | 0% |
5 Year Average Dividend Yield | N/A |
Payout Ratio | 0 |
Last Split Factor | 1:15 |
Financial Highlights
Fiscal Year
Fiscal Year Ends | December 31, 2022 |
Most Recent Quarter (mrq) | December 31, 2022 |
Next Fiscal Year End | December 31, 2023 |
Profitability
Profit Margin | 0% |
Operating Margin (ttm) | 0% |
Gross Margin | 0% |
EBITDA Margin | 0% |
Management Effectiveness
Return on Assets (ttm) | N/A |
Return on Equity (ttm) | N/A |
Income Statement
Revenue (ttm) | N/A |
Revenue Per Share (ttm) | N/A |
Quarterly Revenue Growth (yoy) | N/A |
Gross Profit (ttm) | N/A |
EBITDA | N/A |
Net Income Avi to Common (ttm) | N/A |
Diluted EPS (ttm) | -11.09 |
Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
Total Cash (mrq) | N/A |
Total Cash Per Share (mrq) | N/A |
Total Debt (mrq) | N/A |
Total Debt/Equity (mrq) | N/A |
Current Ratio (mrq) | N/A |
Book Value Per Share (mrq) | 0.603 |
Cash Flow Statement
Operating Cash Flow (ttm) | N/A |
Levered Free Cash Flow (ttm) | N/A |
Profile of Mustang Bio, Inc.
Country | Germany |
State | MA |
City | Worcester |
Address | 377 Plantation Street |
ZIP | 01605 |
Phone | 781 652 4500 |
Website | https://www.mustangbio.com |
Industry | Biotechnology |
Sector(s) | Healthcare |
Full Time Employees | N/A |
Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline focuses on gene therapy programs for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors. The company develops MB-107 and MB-207, a gene therapy program for X-linked severe combined immunodeficiency, a rare genetic immune system condition in which affected patients do not live beyond infancy without treatment. The company also develops MB-102 CAR T therapies for blastic plasmacytoid dendritic cell neoplasm, acute myeloid leukemia, and myelodysplastic syndrome; MB-106 CAR T cell program for B cell non-hodgkin lymphoma and chronic lymphocytic leukemia; MB-104 CAR T for multiple myeloma and light chain amyloidosis; MB-101 CAR T cell program for glioblastoma; MB-103 CAR T for glioblastoma multiforme (GBM) and metastatic breast cancer to brain; MB-105 CAR T for prostate and pancreatic cancers; and MB-108, a next-generation oncolytic herpes simplex virus. It has license agreements with Nationwide Children's Hospital, CSL Behring; Mayo Clin Mayo Clinic; Leiden University Medical Centre; SIRION Biotech GmbH, and Minaris Regenerative Medicine GmbH. The company was incorporated in 2015 and is headquartered in Worcester, Massachusetts.
Q&A For Mustang Bio, Inc. Stock
What is a current 2W6.F stock price?
Mustang Bio, Inc. 2W6.F stock price today per share is 0.32 EUR.
How to purchase Mustang Bio, Inc. stock?
You can buy 2W6.F shares on the Frankfurt exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Mustang Bio, Inc.?
The stock symbol or ticker of Mustang Bio, Inc. is 2W6.F.
Which industry does the Mustang Bio, Inc. company belong to?
The Mustang Bio, Inc. industry is Biotechnology.
How many shares does Mustang Bio, Inc. have in circulation?
The max supply of Mustang Bio, Inc. shares is 109.37M.
What is Mustang Bio, Inc. Price to Earnings Ratio (PE Ratio)?
Mustang Bio, Inc. PE Ratio is 0.00000000 now.
What was Mustang Bio, Inc. earnings per share over the trailing 12 months (TTM)?
Mustang Bio, Inc. EPS is 0 EUR over the trailing 12 months.
Which sector does the Mustang Bio, Inc. company belong to?
The Mustang Bio, Inc. sector is Healthcare.